INGN on XNAS, Health Care, Inogen Inc, job postings
Measures activity, not value. Not investment advice.
Quarterly revenue fell 16% to $77.2M and the stock is down 20% in a year.
BadNet loss of $35.5M over the last 12 months
GoodInstitutional holders rose 7.1%, to 136 from 127 last quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $77.2M, net loss $16.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $105.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$77.2M
-$16.2M
30 Jun 2026
$95.1M
-$3.9M
31 Mar 2026
$85.1M
-$8.3M
31 Dec 2025
$81.7M
-$7.1M
30 Sep 2025
$92.4M
-$5.3M
30 Jun 2025
$92.3M
-$4.2M
31 Mar 2025
$82.3M
-$6.2M
31 Dec 2024
$80.1M
-$9.8M
30 Sep 2024
$88.8M
-$6.0M
30 Jun 2024
$88.8M
-$5.6M
31 Mar 2024
$78.0M
-$14.6M
31 Dec 2023
$75.9M
-$26.6M
30 Sep 2023
$84.0M
-$45.7M
30 Jun 2023
$83.6M
-$9.8M
31 Mar 2023
$72.2M
-$20.3M
31 Dec 2022
$88.1M
-$56.6M
30 Sep 2022
$105.4M
-$9.5M
30 Jun 2022
$103.4M
-$3.4M
31 Mar 2022
$80.4M
-$14.2M
31 Dec 2021
$76.4M
-$22.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$339.1M
$333.7M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+1.6%
+8.1%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$35.5M
-$25.4M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.32
-$1.01
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
44.3%
45.0%
61.3%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-11.6%
-9.2%
5.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-10.5%
-7.6%
-2.7%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-20.0%
-20.0%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$11.3M
-$15.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$96.8M
$123.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$96.8M (net cash)
-$123.2M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.22
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$6.04
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
27.5
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.41
2.6
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
0.12
3.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.88
3.4
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-16%
$77.2M vs $92.4M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+7.1%
136 13F filers vs 127
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
70%
18.2M shares held by 13F filers (30 Sep 2026) of 26.0M outstanding (29 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
5.4%
1.4M shares sold short (30 Oct 2026) of 26.0M outstanding (29 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.8
1.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-8.3%
1.5M shares sold short in the report before, 1.4M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
39%
39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$23K
the 12 months before: $0
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
6
6 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
6 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $5.30 on 20 Nov 2026, -20% over 12 months (12-month range $5.09 to $7.35)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $143K in the last 12 months (the 12 months before: $125K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 10 published in the last 12 months, +43% on the 12 months before.Revenue per quarter. Revenue $77.2M in the latest quarter, -16% on a year earlier.Capital spending per quarter. Capital spending $280K in the latest quarter, -51% on a year earlier.Institutional holders (13F filers). 136 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $76.4M, +3.3% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $80.4M, -7.5% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $103.4M, +1.8% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $105.4M, +13% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $88.1M, +15% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $72.2M, -10% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $83.6M, -19% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $84.0M, -20% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $75.9M, -14% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $78.0M, +8.1% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $88.8M, +6.1% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $88.8M, +5.8% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $80.1M, +5.5% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $82.3M, +5.5% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $92.3M, +4.0% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $92.4M, +4.0% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $81.7M, +2.0% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $85.1M, +3.4% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $95.1M, +3.0% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $77.2M, -16% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $675K, -35% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $1.4M, -9.9% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $870K, -58% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $534K, -56% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $567K, -16% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $1.1M, -21% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $2.0M, +134% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $708K, +33% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $1.4M, +146% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $1.3M, +22% on a year earlier; public on 9 May 2024
Quarter ended 30 Sep 2024: $1.7M, +136% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $329K, -76% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $292K, -78% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $684K; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $568K, -66% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $979K, +198% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $210K, -28% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $711K, +3.9% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $280K, -51% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 152; public on 14 Feb 2022
31 Mar 2022 report: 141; public on 16 May 2022
30 Jun 2022 report: 127; public on 15 Aug 2022
30 Sep 2022 report: 127; public on 14 Nov 2022
31 Dec 2022 report: 124; public on 14 Feb 2023
31 Mar 2023 report: 142; public on 15 May 2023
30 Jun 2023 report: 129; public on 14 Aug 2023
30 Sep 2023 report: 118; public on 14 Nov 2023
31 Dec 2023 report: 119; public on 14 Feb 2024
31 Mar 2024 report: 124; public on 15 May 2024
30 Jun 2024 report: 121; public on 14 Aug 2024
30 Sep 2024 report: 126; public on 14 Nov 2024
31 Dec 2024 report: 130; public on 14 Feb 2025
31 Mar 2025 report: 123; public on 15 May 2025
30 Jun 2025 report: 121; public on 14 Aug 2025
30 Sep 2025 report: 121; public on 14 Nov 2025
31 Dec 2025 report: 126; public on 17 Feb 2026
31 Mar 2026 report: 122; public on 15 May 2026
30 Jun 2026 report: 127; public on 14 Aug 2026
30 Sep 2026 report: 136; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $12K published
Month from 1 Feb 2022: -$12K published
Month from 1 Sep 2025: $23K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $77.2M (30 Sep 2026), 11% below its normal quarter of $87.0M; higher than 49% of its own history.
Two or more unrelated kinds of records unusual within 30 days
15 Jan 2019confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Inogen(INGN): saw 57 13F filers open a new position in the quarter ended 31 Dec 2018, 2.1× the same quarter last year, while it had 4.0M shares sold short in the 15 Mar 2019 report, 5.0× the same report last year. Two unrelated kinds of activity within 105 days.
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2018
Short interest and volume: Short interest spike, became public on 11 Jan 2019
Short interest and volume: Short interest spike, became public on 26 Jan 2019
Short interest and volume: Short interest spike, became public on 12 Feb 2019
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2019
Short interest and volume: Short interest spike, became public on 28 Feb 2019
Short interest and volume: Short interest spike, became public on 12 Mar 2019
Short interest and volume: Short interest spike, became public on 27 Mar 2019
Short interest and volume: Short interest spike, became public on 10 Apr 2019
The quarter ended 31 Dec 2018 against the 8 quarters before it.
this quarterearliernormal: 26See the evidence (9 changes)
Institutional holdings: Many funds opening a new position became public on 14 Nov 2018
Inogen saw 63 13F filers open a new position in the quarter ended 30 Sep 2018, 2.9× the same quarter last year.
This period
63 (the quarter ended 30 Sep 2018)
Normal quarter (median of 8 earlier)
25
Typical spread (median absolute deviation)
2.5
How far from its usual level
+10.3
Same quarter last year
22
History used
1,644 days
the quarter ended 30 Sep 20188 earlier quartersnormal: 25
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Jan 2019
Inogen had 2.8M shares sold short in the 31 Dec 2018 report, 3.3× the same report last year.
This period
2.8M (the 31 Dec 2018 report)
Normal report (median of 20 earlier)
872K
Typical spread (median absolute deviation)
84K
How far from its usual level
+15.8
Same report last year
850K
History used
367 days
the 31 Dec 2018 report20 earlier reportsnormal: 872K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jan 2019
Inogen had 3.0M shares sold short in the 15 Jan 2019 report, 3.8× the same report last year.
This period
3.0M (the 15 Jan 2019 report)
Normal report (median of 21 earlier)
895K
Typical spread (median absolute deviation)
102K
How far from its usual level
+14.0
Same report last year
793K
History used
382 days
the 15 Jan 2019 report21 earlier reportsnormal: 895K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Feb 2019
Inogen had 3.2M shares sold short in the 31 Jan 2019 report, 3.9× the same report last year.
This period
3.2M (the 31 Jan 2019 report)
Normal report (median of 22 earlier)
921K
Typical spread (median absolute deviation)
142K
How far from its usual level
+11.0
Same report last year
840K
History used
398 days
the 31 Jan 2019 report22 earlier reportsnormal: 921K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2019
Inogen saw 57 13F filers open a new position in the quarter ended 31 Dec 2018, 2.1× the same quarter last year.
This period
57 (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
26
Typical spread (median absolute deviation)
2.5
How far from its usual level
+8.4
Same quarter last year
27
History used
1,736 days
the quarter ended 31 Dec 20188 earlier quartersnormal: 26
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 28 Feb 2019
Inogen had 4.1M shares sold short in the 15 Feb 2019 report, 5.7× the same report last year.
This period
4.1M (the 15 Feb 2019 report)
Normal report (median of 23 earlier)
947K
Typical spread (median absolute deviation)
160K
How far from its usual level
+13.4
Same report last year
730K
History used
413 days
the 15 Feb 2019 report23 earlier reportsnormal: 947K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Mar 2019
Inogen had 3.9M shares sold short in the 28 Feb 2019 report, 5.5× the same report last year.
This period
3.9M (the 28 Feb 2019 report)
Normal report (median of 24 earlier)
947K
Typical spread (median absolute deviation)
171K
How far from its usual level
+11.8
Same report last year
715K
History used
426 days
the 28 Feb 2019 report24 earlier reportsnormal: 947K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Mar 2019
Inogen had 4.0M shares sold short in the 15 Mar 2019 report, 5.0× the same report last year.
This period
4.0M (the 15 Mar 2019 report)
Normal report (median of 24 earlier)
954K
Typical spread (median absolute deviation)
207K
How far from its usual level
+10.0
Same report last year
814K
History used
441 days
the 15 Mar 2019 report24 earlier reportsnormal: 954K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2019
Inogen had 4.1M shares sold short in the 29 Mar 2019 report, 5.0× the same report last year.
This period
4.1M (the 29 Mar 2019 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
311K
How far from its usual level
+6.6
Same report last year
814K
History used
455 days
the 29 Mar 2019 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
saw 25 13F filers open a new position in the quarter ended 31 Mar 2024, 1.1× the same quarter last year.
Same quarter last year: 22; its normal quarter is 14.5.
See the evidence
This period
25 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
14.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+3.5
Same quarter last year
22
History used
3,653 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 14.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 878K shares sold short in the 15 Mar 2022 report, 1.6× the same report last year.
Same report last year: 559K; its normal report is 556K.
See the evidence
This period
878K (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
556K
Typical spread (median absolute deviation)
53K
How far from its usual level
+4.1
Same report last year
559K
History used
1,537 days
the 15 Mar 2022 report24 earlier reportsnormal: 556K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 70 entries; narrow the window or the kind of data to see older ones.
Not listed: 271 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001294133
Ticker
INGN
Domain
inogen.com
Employer name
INOGEN (1 unverified)
Hq location
MA|BEVERLY|01915 (1 unverified)
Name
Inogen Europe, B.V, Inogen Inc, Physio Assist SAS
Uei
LYCHKW41FL14
DOL H-1B labor condition applications and PERM certifications178 data points1 Oct 2019 to 6 Jul 2026
SEC Form 13F institutional holdings459 data points31 Mar 2014 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)158 records13 Jan 2016 to 19 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1061 data points31 Dec 2009 to 29 Oct 2026
SEC Form 4 insider transactions163 records, 516 data points19 Jan 2016 to 6 Jul 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards111 data points27 Sep 2011 to 3 Sep 2025